What one share of Aurinia Pharmaceuticals holds
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”).
Aurinia Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.28 |
|---|---|
| Profit | $2.30 |
| Cash and investments | $1.35 |
| Book value | $4.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.66 | $0.00 | −$0.53 | — | $1.02 |
| 2017 | — | −$0.92 | $0.00 | −$0.54 | — | $2.12 |
| 2018 | — | −$0.63 | $0.00 | −$0.61 | — | $1.59 |
| 2019 | — | −$0.95 | $0.00 | −$0.68 | — | $2.67 |
| 2020 | $0.42 | −$0.87 | — | — | — | $3.22 |
| 2021 | $0.35 | −$1.40 | — | — | — | $3.38 |
| 2022 | $0.94 | −$0.76 | — | — | — | $2.85 |
| 2023 | $1.23 | −$0.54 | — | — | — | $2.63 |
| 2024 | $1.61 | $0.04 | — | — | — | $2.68 |
| 2025 | $2.04 | $2.07 | — | — | — | $4.39 |
Common questions about Aurinia Pharmaceuticals
How much does one share of Aurinia Pharmaceuticals earn?
Over the last 12 months, each share of Aurinia Pharmaceuticals earned $2.30 of profit on $2.28 of sales, keeping about 101¢ of every $1 (profit margin).
Does Aurinia Pharmaceuticals pay a dividend?
Aurinia Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aurinia Pharmaceuticals’s book value per share?
Aurinia Pharmaceuticals’s book value is $4.63 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aurinia Pharmaceuticals have?
Each share of Aurinia Pharmaceuticals has $1.35 of cash and investments, as of June 30, 2026.
Has Aurinia Pharmaceuticals bought back shares?
Aurinia Pharmaceuticals’s share count rose about 293% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.